CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
alone in participants with untreated, unresectable or metastatic melanoma. Participants randomized to the pembrolizumab monotherapy arm who ...
Phase 3
Detroit, Michigan, United States and 47 other locations
The study is focused on patients with a type of skin cancer known as melanoma. The aim of the study is to see how safe and effective the com...
Phase 3
Detroit, Michigan, United States and 15 other locations
binimetinib, and pembrolizumab) given together for the treatment of melanoma that:* is advanced or metastatic (spread to other parts of the ...
Phase 3
Farmington Hills, Michigan, United States and 227 other locations
and overall survival (OS) for patients with NRAS-mutant (NRASm) melanoma who are randomized to receive the combination of naporafenib + tram...
Phase 3
Detroit, Michigan, United States of America and 31 other locations
efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma...
Phase 3
Ann Arbor, Michigan, United States and 49 other locations
A Phase 2 study to investigate the efficacy and safety of lerapolturev alone or in combination with a programmed death receptor-1 (anti-PD-1) inhibit...
Phase 2
Detroit, Michigan, United States and 11 other locations
to assess nivolumab plus relatlimab fixed-dose combination (FDC) versus nivolumab alone in participants with completely resected stage III-IV melanoma...
Phase 3
Ann Arbor, Michigan, United States and 171 other locations
be those with pathological diagnosis of unresectable or metastatic melanoma who are progressing or have progressed on either pembrolizumab o...
Phase 2
Ann Arbor, Michigan, United States and 32 other locations
combined with nivolumab in patients with unresectable or metastatic melanoma. A separate open-label cohort of adults with new, progressive b...
Phase 3
Toledo, Ohio, United States and 138 other locations
this study is to determine whether relatlimab in combination with nivolumab is more effective than nivolumab by itself in treating unresectable melanoma...
Phase 2, Phase 3
Ann Arbor, Michigan, United States and 126 other locations
Clinical trials
Research sites
Resources
Legal